Skip to main content

Peer Review reports

From: Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer

Original Submission
16 Nov 2021 Submitted Original manuscript
9 Dec 2021 Reviewed Reviewer Report
11 Dec 2021 Reviewed Reviewer Report
12 Dec 2021 Reviewed Reviewer Report
18 Mar 2022 Author responded Author comments - Kosuke Hiramatsu
Resubmission - Version 2
18 Mar 2022 Submitted Manuscript version 2
29 Mar 2022 Author responded Author comments - Kosuke Hiramatsu
Resubmission - Version 3
29 Mar 2022 Submitted Manuscript version 3
1 Apr 2022 Author responded Author comments - Kosuke Hiramatsu
Resubmission - Version 4
1 Apr 2022 Submitted Manuscript version 4
14 Apr 2022 Author responded Author comments - Kosuke Hiramatsu
Resubmission - Version 5
14 Apr 2022 Submitted Manuscript version 5
30 Apr 2022 Reviewed Reviewer Report
1 May 2022 Reviewed Reviewer Report
2 May 2022 Reviewed Reviewer Report
14 May 2022 Author responded Author comments - Kosuke Hiramatsu
Resubmission - Version 6
14 May 2022 Submitted Manuscript version 6
3 Jun 2022 Reviewed Reviewer Report
7 Jun 2022 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
16 Jun 2022 Editorially accepted
21 Jun 2022 Article published 10.1186/s12885-022-09789-6

You can find further information about peer review here.

Back to article page